Axsome Therapeutics price target raised to $160 from $140 at Wells Fargo
Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...
Barron's3d
Viking Therapeutics Inc.
Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and ...
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shopify Earnings Confused the Market. Why the Stock Is Trading All Over the Place.
Shopify turned in quarterly revenue and gross merchandise volume above estimates, but it wasn’t enough to lift shares. Shopify stock fell 8.4% to $109.85 in premarket trading Tuesday. For its fourth ...
marketinference4d
Can There Be More Upside for Axsome Therapeutics (AXSM) if It Is Overvalued?
It's been a strong day for Axsome Therapeutics. Its shares are now trading at $127.02, marking a 20.1% change since the ...
Stocks Settle Higher and Brush Aside Tariff Concerns
Real-time index price for Nasdaq Insurance Index (INSR), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Stocks Push Higher on Strength in Metal Producers and Chip Stocks
Real-time index price for TSX Canadian Dividend Aristocrats Index (TXDV), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Investing14d
FDA approves Axsome's novel migraine treatment SYMBRAVO
This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...
FiercePharma14d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is approved for the acute ...
Morningstar14d
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ ... or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
Pharm Exec15d
FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura
The FDA has approved Axsome Therapeutics’ Symbravo (meloxicam and rizatriptan), a novel acute treatment for adults with migraine with or without aura. According to the company, Symbravo employs Axsome ...